Botulinum Toxin Type A / 100units
South Korea’s leading botulinum toxin producer, Medy-Tox Inc. has launched Coretox.
a new botulinum toxin type A product designed to reduce the risk of drug resistance, an ongoing concern after repeated injections.
It marks the third product in the company’s Botox product line, following the first locally developed Botox product, Medytoxin, and the world’s first Botox product, Medytoxin.
Medytoxin and the world’s first liquid toxin formulation, Innotox.
Medy-Tox was the first company in the world to develop three botulinum toxin formulations.
The company says the reduced resistance of Coretox is created by eliminating non-toxic proteins not associated with efficacy and refining only the neurotoxin.
Due to the nature of regular injections, patients may develop resistance to Botox treatments, depending on the number, duration, and dosage administered.
Specifically, for the first time in the world, Medy-Tox excludes the animal component of Clostridium botulinum culture from the manufacturing process.
and used human serum albumin as a stabilizer in the finished product to reduce the potential for infection with bloodborne pathogens.
In conjunction with the launch of Coretox, Medy-Tox plans to launch a large-scale campaign to
to publicize the risk of botulinum toxin treatment resistance at national and international conferences and related events.
